proinflammatory cytokine

Overview

Proinflammatory cytokines are a class of small signaling glycoproteins and Peptides secreted predominantly by activated immune cells — including macrophages, dendritic cells, T lymphocytes, and natural killer (NK) cells — that orchestrate and amplify the inflammatory response. The most extensively studied members include tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (CXCL8/IL-8), interleukin-17 (IL-17), and interferon-gamma (IFN-γ). These molecules act on target cells by binding to specific surface receptors and activating downstream intracellular cascades — most prominently the nuclear factor kappa B (NF-κB) signaling pathway, the JAK2/STAT3 signaling pathway, the MAPK pathway, and the PI3K/AKT/mTOR pathway — leading to the transcription of additional inflammatory mediators, recruitment of immune effector cells, and initiation of tissue remodeling processes. While transient proinflammatory cytokine activity is essential for host defense against pathogens and coordinated wound repair, chronic or dysregulated secretion underpins the pathogenesis of a broad spectrum of diseases including autoimmune disorders, metabolic syndrome, neurodegeneration, cardiovascular disease, and cancer.

The biological significance of proinflammatory cytokines extends well beyond acute infection. They serve as critical mediators of innate-adaptive immune crosstalk, modulating T-lymphocyte differentiation (including Th17 cell polarization driven by IL-6 and TGF-β1), macrophage polarization between pro-inflammatory M1 and reparative M2 phenotypes, and the activation of the NLRP3 inflammasome, which governs caspase-1-dependent processing of IL-1β and IL-18. anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β1) provide counterregulatory balance. The ratio of proinflammatory to anti-inflammatory cytokines is therefore a key determinant of tissue homeostasis, and its disruption is a major therapeutic target across medicine.

Focus of Latest Publications

Recent publications have demonstrated that proinflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) are central mediators across diverse pathological conditions ranging from neurodegenerative diseases to metabolic dysfunction and cancer. In neuroinflammation-associated cognitive decline, these cytokines are upregulated through the TLR4/NF-κB signaling pathway, with studies showing that reducing their expression correlates with improved learning and memory outcomes in animal models. Similarly, in advanced maternal age pregnancies, elevated IL-6 in the uterine microenvironment exacerbates macrophage senescence and associated adverse pregnancy outcomes. Beyond the brain, proinflammatory cytokines contribute to systemic complications: in metabolic dysfunction-associated steatohepatitis, TNF-α induces pro-fibrotic signaling and exacerbates inflammatory responses under nutrient stress; in psoriatic arthritis, elevated proinflammatory cytokine levels correlate with increased disease activity as measured by clinical indices; and in triple-negative breast cancer, tumor-associated macrophages secrete these cytokines to promote epithelial-to-mesenchymal transition and metastatic lung colonization.

Mechanistic studies reveal that proinflammatory cytokine production is regulated through overlapping signaling cascades, with particular emphasis on the IL-6/JAK2/STAT3, NF-κB/MAPK, and TLR-mediated pathways. Senescent cells and polarized macrophages serve as major sources of these cytokines, with senescence-associated secretory phenotypes promoting IL-1β-driven invasion in squamous cell carcinoma and contributing to glioma microenvironment remodeling. Transcriptomic and proteomic analyses demonstrate that reducing these cytokines correlates with downregulation of genes involved in matrix metalloproteinase expression, fibrosis, and immune suppression, suggesting broad network-level effects. Additionally, proinflammatory cytokine levels have been validated as biomarkers for disease activity and severity, with IL-6 and TNF-α showing associations with stroke risk, infection susceptibility, and therapeutic response across multiple conditions.

Therapeutic approaches targeting these cytokines have included histone deacetylase inhibitors, natural compounds with anti-inflammatory properties, TNF-α receptor antagonists, and multipathway inhibitors identified through network pharmacology. In preclinical studies, vorinostat reduced hippocampal expression of IL-6, IL-1β, and TNF-α while improving cognitive recovery, with potentially sex-specific protective effects in females. Natural flavonoids such as genistein and luteolin suppressed IL-1β and TNF-α through NF-κB and MAPK inhibition in chondrocyte and adipocyte models, while salvianolic acid A and traditional Chinese medicine formulations demonstrated multi-target engagement with these cytokine pathways. Physical interventions including electroacupuncture reduced serum TNF-α and IL-6 while increasing anti-inflammatory interleukins, and strength training during chemotherapy produced differential changes in IL-6 and IL-17 expression. Pharmacological blockade of cytokine receptors (CCR5, CXCR2, IL1R1) successfully disrupted pro-metastatic macrophage-tumor cell crosstalk in breast cancer models, demonstrating the therapeutic potential of interrupting these signaling axes.

These findings collectively establish proinflammatory cytokines as tractable therapeutic targets across neurological, metabolic, immunological, and oncological disorders. The consistency of elevated IL-6, TNF-α, and IL-1β across diverse disease contexts, combined with the efficacy of multi-target interventions addressing their upstream regulation and receptor signaling, suggests that cytokine modulation strategies warrant further clinical translation, particularly given the emerging evidence for patient-specific responses and sex-dependent differences in cytokine-driven pathology.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42406171)
• NEWJul Age-Associated Senescence of Decidual Macrophages: A Key Mediator of Adverse Pregnancy Outcomes in Advanced Maternal Age. (Aging cell, 2026, PMID 42387987): "On the other hand, elevated IL-6 in the uterine microenvironment exacerbates senescence."
• NEWJul BIENs: biomimetic interface encoding on Fe3O4@Au nanoplatforms for multiplexed cytokine profiling. (Mikrochimica acta, 2026, PMID 42384130): "Herein, we report a multiplexed electrochemical biosensing platform based on biomimetic interfacial encoding using Fe3O4@Au nanoplatforms (BIENs)."
• NEWJul A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PloS one, 2026, PMID 42384725): "Protein-protein interaction analysis using STRING and Cytoscape revealed fourteen key hub nodes, including AKT1, BCL2, CASP3, CTNNB1, EGFR, ESR1, GAPDH, HSP90AA1, HSP90AB1, IL6, JUN, SRC, STAT3, and TNF."
• NEWJun Lower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study. (Rheumatology international, 2026, PMID 42377589): "The discriminative performance of the CALLY index was similar to that of CRP (AUC 0.724 vs. 0.738; p=0.42)."
• NEWJun Role of procalcitonin and interleukin-6 in early detection of infection in patients undergoing conversion from external fixation to definitive internal fixation in open fractures- A pilot study. (European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026, PMID 42347995): "Novel biomarkers procalcitonin and interleukin-6 have established a role in periprosthetic joint infections."
• NEWJun In silico screening and molecular analyses identify apigenin from Scutellaria barbata as a potent AKT1 inhibitor in breast cancer. (PloS one, 2026, PMID 42348584): "Network analysis identified AKT1, IL6 and TNF as central hub targets, significantly enriched in the PI3K-Akt, MAPK, and TNF signaling pathways."
• NEWJul The Effect of Strength Training During Chemotherapy in Women With Breast Cancer on Serum Cytokine Concentrations and Skeletal Muscle Autophagy-Related Proteins. (European journal of sport science, 2026, PMID 42350900): "Serum cytokines (IFN-γ, IL-1RA, IL-6, IL-8, IL-10, IL-17, MCP-1, TNF-α) were quantified, and muscle biopsies were analyzed for autophagy- and heat-shock-related proteins."
• NEWJun Elucidating the therapeutic targets and multi-target mechanisms of salvianolic acid A for diabetic nephropathy. (Mammalian genome : official journal of the International Mammalian Genome Society, 2026, PMID 42342966): "Molecular docking demonstrated strong binding affinities of salvianolic acid A to the domains of FYN, AKR1B1, TNF, GALK1, HMGCR, MAP2K2, SCN4A, and ITGA5."
• NEWJul Oxidative Stress Induced Senescent Macrophage-Driven Squamous Cell Carcinoma Invasion via Glutamine Metabolic Reprogramming. (Aging cell, 2026, PMID 42333921): "Mechanistically, IL-1β secreted by senescent macrophages promoted tumor invasion by downregulating IL-1R2 and activating NF-κB signaling in SCC cells."